Resistance to topoisomerase poisons due to loss of DNA mismatch repair

International Journal of Cancer

Volumn 93, Issue 4, 2001, Pages 571-576

  Fedier, Andr ^a   Schwarz, Viola A ^a   Walt, Heinrich ^a   Carpini, Renato Delli ^a   Haller, Urs ^a   Fink, Daniel ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Breast cancer; DNA mismatch repair; Drug resistance; Topoisomerase poisons

Indexed keywords

CAMPTOTHECIN; DNA; DNA TOPOISOMERASE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; GENE PRODUCT; MITOXANTRONE; PROTEIN MLH1; PROTEIN MSH2; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; BASE MISPAIRING; BREAST CARCINOMA; CANCER RESISTANCE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; MICROSATELLITE INSTABILITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; BASE PAIR MISMATCH; BREAST NEOPLASMS; CARRIER PROTEINS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; ENZYME INHIBITORS; EPIRUBICIN; FEMALE; HUMANS; INTERCALATING AGENTS; MITOXANTRONE; MUTS HOMOLOG 2 PROTEIN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PACLITAXEL; PROTO-ONCOGENE PROTEINS; TAXOIDS;

EID: 0035882531     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1356     Document Type: Article

References (37)

1. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis
2. Identification of mismatch repair genes and their role in the development of cancer
3. Microsatellite instability is correlated with lymph node-positive breast cancer
4. Microsatellite instability in medullary breast carcinomas
5. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft
6. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells
7. The role of DNA mismatch repair in platinum drug resistance
8. Mismatch repair proficiency and in vitro response to 5-fluorouracil
9. Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line
10. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumor cells
11. The role of DNA mismatch repair in drug resistance
12. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation
13. Correction of hypermutability, N-methyl-N′-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6
14. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines
15. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells
16. Purified human MSH2 protein binds to DNA containing mismatched nucleotides
17. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells
18. hMSH2 form specific mispair-binding complexes with hMSH3 and hMSH6
19. Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs
20. DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: Implications for tolerance to DNA methylation damage
21. An alkylation-tolerant, mutator human cell line is deficient in strandspecific mismatch repair
22. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
23. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues
24. Structure and mechanism of DNA topoisomerase II
25. An overview of topoisomerase I-targeting agents
26. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines
27. Mechanisms of topoisomerase I inhibition by anticancer drugs
28. 4-methylthymine, or the cisplatind(GpG) adduct
29. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin
30. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
31. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer
32. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis
33. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
34. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin
35. Loss of DNA mismatch repair in acquired resistance to cisplatin
36. Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer
37. Reduced MLH1 expression in breast tumors after primary, chemotherapy predicts disease-free survival